Hematopoietic stem cell transplantation in Saudi Arabia between 1984 and 2016: Experience from four leading tertiary care hematopoietic stem cell transplantation centers.


Journal

Hematology/oncology and stem cell therapy
ISSN: 2589-0646
Titre abrégé: Hematol Oncol Stem Cell Ther
Pays: Saudi Arabia
ID NLM: 101468532

Informations de publication

Date de publication:
Sep 2021
Historique:
received: 13 07 2020
accepted: 26 07 2020
pubmed: 6 9 2020
medline: 18 9 2021
entrez: 5 9 2020
Statut: ppublish

Résumé

Saudi Arabia is the largest of the Arabian Gulf countries with a total population of 33.41 million as of 2017. This report summarizes the experience from four leading tertiary care hematopoietic stem cell transplantation (HSCT) centers in Saudi Arabia representing more than 90% of all HSCTs performed in the country. Between 1984 and 2016, a total of 6,184 HSCTs were performed. Of these, 3,586 HSCTs were performed in adults and 2,598 HSCTs were performed in pediatric patients. Malignancy was the main indication for transplantation (47%). While most transplants were performed from an identical sibling donor, HSCTs from cord blood, unrelated and, more recently, haploidentical donors have also been performed. Relative shortage of HSCT bed capacity is perceived to be a limiting factor in Saudi Arabia. Lately, more HSCT centers are emerging with rapid growth, which may significantly improve the access to HSCT in the country in the near future.

Identifiants

pubmed: 32888899
pii: S1658-3876(20)30141-2
doi: 10.1016/j.hemonc.2020.07.008
pii:
doi:

Types de publication

Historical Article Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

169-178

Informations de copyright

Copyright © 2020 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Marwan Shaheen (M)

King Faisal Specialist Hospital and Research Centre, Hematopoietic Stem Cell Transplantation, Riyadh, Saudi Arabia. Electronic address: mshaheen@kfshrc.edu.sa.

Fahad Almohareb (F)

King Faisal Specialist Hospital and Research Centre, Hematopoietic Stem Cell Transplantation, Riyadh, Saudi Arabia.

Naif Aljohani (N)

King Faisal Specialist Hospital and Research Centre, Hematopoietic Stem Cell Transplantation, Jeddah, Saudi Arabia.

Mouhab Ayas (M)

King Faisal Specialist Hospital and Research Centre, Hematopoietic Stem Cell Transplantation, Riyadh, Saudi Arabia.

Naeem Chaudhri (N)

King Faisal Specialist Hospital and Research Centre, Hematopoietic Stem Cell Transplantation, Riyadh, Saudi Arabia.

Ibraheem Abosoudah (I)

King Faisal Specialist Hospital and Research Centre, Hematopoietic Stem Cell Transplantation, Jeddah, Saudi Arabia.

Sultan Alotaibi (S)

Prince Sultan Military Medical City, Riyadh, Saudi Arabia.

Mohammed Alshahrani (M)

Prince Sultan Military Medical City, Riyadh, Saudi Arabia.

Fahad Alsharif (F)

King Faisal Specialist Hospital and Research Centre, Hematopoietic Stem Cell Transplantation, Riyadh, Saudi Arabia.

Saad Akhtar (S)

King Faisal Specialist Hospital and Research Centre, Hematopoietic Stem Cell Transplantation, Riyadh, Saudi Arabia.

Hind Alhumaidan (H)

King Faisal Specialist Hospital and Research Centre, Hematopoietic Stem Cell Transplantation, Riyadh, Saudi Arabia.

Walid Rasheed (W)

King Faisal Specialist Hospital and Research Centre, Hematopoietic Stem Cell Transplantation, Riyadh, Saudi Arabia.

Feras Alfraih (F)

King Faisal Specialist Hospital and Research Centre, Hematopoietic Stem Cell Transplantation, Riyadh, Saudi Arabia.

Khalid Al-Anazi (K)

King Fahad Specialist Hospital, Dammam, Saudi Arabia.

Hani Alhashmi (H)

King Fahad Specialist Hospital, Dammam, Saudi Arabia.

Saad Al-Daama (S)

King Fahad Specialist Hospital, Dammam, Saudi Arabia.

Amr Hanbali (A)

King Faisal Specialist Hospital and Research Centre, Hematopoietic Stem Cell Transplantation, Riyadh, Saudi Arabia.

Khalid Alsaleh (K)

King Khalid University Hospital, Riyadh, Saudi Arabia; Department of Medicine, College of Medicine, King Saud University, Riyadh, Kingdom of Saudi Arabia.

Hazzaa Alzahrani (H)

King Faisal Specialist Hospital and Research Centre, Hematopoietic Stem Cell Transplantation, Riyadh, Saudi Arabia.

Khalid Ibrahim (K)

Prince Sultan Military Medical City, Riyadh, Saudi Arabia.

Moheeb Alawwami (M)

King Faisal Specialist Hospital and Research Centre, Hematopoietic Stem Cell Transplantation, Riyadh, Saudi Arabia.

Bassim Albeirouti (B)

King Faisal Specialist Hospital and Research Centre, Hematopoietic Stem Cell Transplantation, Jeddah, Saudi Arabia.

Amal Albeihany (A)

King Fahad Hospital, Madinah, Saudi Arabia.

Amal Alabdulwahab (A)

King Abdullah Medical City, Makkah, Saudi Arabia.

Ibraheem Motabi (I)

King Fahad Medical City, Riyadh, Saudi Arabia.

Syed Z A Zaidi (SZA)

King Fahad Medical City, Riyadh, Saudi Arabia.

Syed O Ahmed (SO)

King Faisal Specialist Hospital and Research Centre, Hematopoietic Stem Cell Transplantation, Riyadh, Saudi Arabia.

Abdullah Aljefri (A)

King Faisal Specialist Hospital and Research Centre, Hematopoietic Stem Cell Transplantation, Riyadh, Saudi Arabia.

Fazal Hussain (F)

King Faisal Specialist Hospital and Research Centre, Hematopoietic Stem Cell Transplantation, Riyadh, Saudi Arabia.

Ali Alahmari (A)

King Faisal Specialist Hospital and Research Centre, Hematopoietic Stem Cell Transplantation, Riyadh, Saudi Arabia.

Shahrukh Hashmi (S)

King Faisal Specialist Hospital and Research Centre, Hematopoietic Stem Cell Transplantation, Riyadh, Saudi Arabia.

Hassan Elsolh (H)

King Faisal Specialist Hospital and Research Centre, Hematopoietic Stem Cell Transplantation, Riyadh, Saudi Arabia.

Amal Alseraihy (A)

King Faisal Specialist Hospital and Research Centre, Hematopoietic Stem Cell Transplantation, Riyadh, Saudi Arabia.

Mahmoud Aljurf (M)

King Faisal Specialist Hospital and Research Centre, Hematopoietic Stem Cell Transplantation, Riyadh, Saudi Arabia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH